Drugs / SCOV1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05047445 | Oct 2021 → Dec 2022 | COVID-19 | Scancell Ltd | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-02-13 | Scancell Ltd | Results Scancell announces positive response in COVIDITY trial scancell.co.uk ↗ |
| 2022-03-29 | Scancell Ltd | Regulatory Broadening of COVIDITY Phase 1 clinical trial in South Africa scancell.co.uk ↗
SAHPRA approves clinical trial amendment allowing testing of COVIDITY vaccine candidate in a real-world setting |
| 2022-01-31 | Scancell Ltd | Results Update on COVIDITY Phase 1 clinical trial in South Africa scancell.co.uk ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-02-13 | Scancell Ltd | Scancell announces positive response in COVIDITY trial scancell.co.uk ↗ |
| 2022-03-29 | Scancell Ltd | Broadening of COVIDITY Phase 1 clinical trial in South Africa scancell.co.uk ↗ |
| 2022-01-31 | Scancell Ltd | Update on COVIDITY Phase 1 clinical trial in South Africa scancell.co.uk ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCOV1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05047445 ↗ |
| Modality | Vaccine | “two DNA plasmid vaccines (SCOV1 and SCOV2)” NCT05047445 ↗ |